These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37321166)

  • 1. COVID-19 as a catalyst for vaccine manufacturing: A South African experience.
    Moore PL; Gray G
    Cell Host Microbe; 2023 Jun; 31(6):839-842. PubMed ID: 37321166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
    Kana BD; Arbuthnot P; Botwe BK; Choonara YE; Hassan F; Louzir H; Matsoso P; Moore PL; Muhairwe A; Naidoo K; Ndomondo-Sigonda M; Madhi SA
    Lancet Infect Dis; 2023 Aug; 23(8):e288-e300. PubMed ID: 37290473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccines and vaccination: how prepared is Africa?
    Ariyo OE; Oladipo EK; Osasona OG; Obe O; Olomojobi F
    Pan Afr Med J; 2021; 39():107. PubMed ID: 34512843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access considerations for a COVID-19 vaccine for South Africa.
    Bangalee V; Suleman F
    S Afr Fam Pract (2004); 2020 Oct; 62(1):e1-e4. PubMed ID: 33179954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building global vaccine manufacturing capacity: Spotlight on Africa.
    Rubin Thompson LJ; Grubo M; Veller M; Badenhorst RH; Nott J; Debruyne L; Makadzange T; Nicolaou S; Stanberry L; Sall A; James WG
    Vaccine; 2023 Jun; 41(27):4050-4056. PubMed ID: 37173266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccinology landscape in Africa.
    Baptista S; Naidoo S; Suliman S; Nepolo E; Kanoi BN; Gitaka J; Blessing OM; Enany S
    Front Immunol; 2022; 13():955168. PubMed ID: 36544758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equal access of COVID-19 vaccine distribution in Africa: Challenges and way forward.
    Aborode AT; Olofinsao OA; Osmond E; Batubo AP; Fayemiro O; Sherifdeen O; Muraina L; Obadawo BS; Ahmad S; Fajemisin EA
    J Med Virol; 2021 Sep; 93(9):5212-5215. PubMed ID: 34009657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The experience of disproportionate supplies of COVID-19 vaccines to Africa: the need for Africa to decolonize its public health response.
    Adeoye AO; Okunola JL; Fakunle SO
    Pan Afr Med J; 2023; 44():54. PubMed ID: 37128613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?
    Cooper S; van Rooyen H; Wiysonge CS
    Expert Rev Vaccines; 2021 Aug; 20(8):921-933. PubMed ID: 34252336
    [No Abstract]   [Full Text] [Related]  

  • 10. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.
    Bright B; Babalola CP; Sam-Agudu NA; Onyeaghala AA; Olatunji A; Aduh U; Sobande PO; Crowell TA; Tebeje YK; Phillip S; Ndembi N; Folayan MO
    Global Health; 2021 Mar; 17(1):24. PubMed ID: 33658050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covid-19: South African disclosures reveal secretive world of nations' vaccine contracts.
    Dyer O
    BMJ; 2024 May; 385():q1172. PubMed ID: 38806192
    [No Abstract]   [Full Text] [Related]  

  • 12. Dealing with vaccine hesitancy in Africa: the prospective COVID-19 vaccine context.
    Afolabi AA; Ilesanmi OS
    Pan Afr Med J; 2021; 38():3. PubMed ID: 33520072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Perspective on Nanotechnology and COVID-19 Vaccine Research and Production in South Africa.
    Dube A; Egieyeh S; Balogun M
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccine demand protest might have increased vaccine acceptance and uptake in South Africa.
    Mavundza EJ; Ndwandwe D; Wiysonge CS
    Hum Vaccin Immunother; 2022 Nov; 18(5):2064691. PubMed ID: 35435798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine roll-out in South Africa: The added value of wastewater surveillance for SARS-CoV-2.
    Street RA; Mathee A; Johnson R; Muller CJF; Louw J; Mdhluli M; Gelderblom HC; Gray GE
    S Afr Med J; 2021 May; 111(6):524-525. PubMed ID: 34382559
    [No Abstract]   [Full Text] [Related]  

  • 16. The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries.
    Nsanzimana S; Gupta A; Uwizihiwe JP; Haggstrom J; Dron L; Arora P; Park JJH
    Am J Trop Med Hyg; 2021 Jul; 105(3):561-563. PubMed ID: 34270458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What could fair allocation of an efficacious COVID-19 vaccine look like in South Africa?
    Moodley K; Rossouw T
    Lancet Glob Health; 2021 Feb; 9(2):e106-e107. PubMed ID: 33160456
    [No Abstract]   [Full Text] [Related]  

  • 18. The Scientists' Collective 10-point proposal for equitable and timeous access to COVID-19 vaccine in South Africa.
    Gray G; Van der Heever A; Madhi S; McIntyre J; Kana B; Stevens W; Sanne I; Richards G; Abdullah F; Mendelson M; Dasoo A; Nel J; Wulfsohn A; Blumberg L; Venter F
    S Afr Med J; 2020 Dec; 111(2):89-94. PubMed ID: 33944712
    [No Abstract]   [Full Text] [Related]  

  • 19. Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
    Shivji R; Conocchia R; Korakianiti E; Jekerle V
    Vaccine; 2022 Sep; 40(38):5539-5541. PubMed ID: 35779964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing Vaccinology Capacity: Education and Efforts in Vaccine Development and Manufacturing across Africa.
    Sinumvayo JP; Munezero PC; Tope AT; Adeyemo RO; Bale MI; Nyandwi JB; Haakuria VM; Mutesa L; Adedeji AA
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.